Safety, tolerability, and serum/tear pharmacokinetics of human recombinant epidermal growth factor eyedrops in healthy subjects
Hyounggyoon Yoo1,6, Seonghae Yoon1,4, In-Jin Jang1,3, Kyung-Sang Yu1,3, Joon Young Hyon2,5, Jungi Hwang7, Inyoung Hwang1,3, Jung Sunwoo1,3, Jae-Yong Chung1,4
1. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, Republic of Korea
2. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
3. Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Republic of Korea
4. Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5. Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
6. Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, Seongnam, Republic of Korea
7. Department of Clinical Pharmacology and Therapeutics, Chungbuk National University Hospital, Cheongju, Republic of Korea
*The authors confirm that the Principal Investigator for this paper is Jae-Yong Chung and that he had direct clinical responsibility for study participants.